- Home
- KINS vs AMRN Comparison
KINS vs AMRN Comparison
Compare KINS & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KINS | AMRN |
|---|---|---|
| Founded | 1886 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.5M | 287.9M |
| IPO Year | 2013 | 1998 |
Fundamental Metrics
Financial Performance| Metric | KINS | AMRN |
|---|---|---|
| Price | $18.72 | $11.27 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $12.50 |
| AVG Volume (30 Days) | 57.4K | ★ 62.0K |
| Earning Date | 11-05-2026 | 11-02-2026 |
| Dividend Yield | ★ 1.28% | N/A |
| EPS Growth | ★ 94.59 | 55.00 |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $214,867,301.00 | $181,104,000.00 |
| Revenue This Year | $18.83 | N/A |
| Revenue Next Year | $15.85 | N/A |
| P/E Ratio | $28.27 | ★ N/A |
| Revenue Growth | 38.50 | ★ 39.22 |
| 52 Week Low | $13.83 | $11.25 |
| 52 Week High | $20.90 | $20.90 |
Technical Indicators
Market Signals| Indicator | KINS | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 49.95 | 18.14 |
| Support Level | $18.68 | N/A |
| Resistance Level | $19.31 | $15.34 |
| Average True Range (ATR) | 0.46 | 0.35 |
| MACD | 0.07 | -0.08 |
| Stochastic Oscillator | 75.41 | 3.20 |
Price Performance
Historical ComparisonAbout KINS Kingstone Companies Inc.
Kingstone Companies Inc offers property and casualty insurance products through its subsidiary engaged in writing business through retail and wholesale agents and brokers. Its products include Personal lines, Livery physical damage, and Others. It operates in single segment, property and casualty insurance. It derives substantially all of its revenue from KICO, including revenues from earned premiums, ceding commissions from quota share reinsurance, net investment income generated from its investment portfolio, and net realized gains and losses on investment securities.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.